Quantcast

US Oncology Affiliated Physicians to Present and Receive Honors at ASCO

May 20, 2010

THE WOODLANDS, Texas, May 20 /PRNewswire/ — US Oncology, Inc., the nation’s leading integrated oncology company, announced today that two physicians affiliated with US Oncology Research will be honored at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 4 – 8 at McCormick Place in Chicago.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100520/DA08694)

Daniel D. Von Hoff, MD, FACP, is the recipient of the 2010 David A. Karnofsky Memorial Award and Lecture for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer. Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He currently serves as physician-in-chief for the Translational Genomics Institute in Phoenix, Arizona, chief scientific officer at US Oncology and Scottsdale Healthcare, and clinical professor of medicine at The University of Arizona College of Medicine. Dr. Von Hoff also serves as lead physician of the Translational Oncology Program (TOP) for US Oncology. The TOP program offers Phase I clinical trial studies, which often offer first-in-human agents. He is also responsible for bringing many new compounds to US Oncology Research for studies.

John V. Cox, DO, FACP, Texas Oncology is a recipient of the ASCO Statesman Award. This award recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients of the 2010 Statesman Award have given 20 years of volunteer service.

In addition, more than 50 physicians affiliated with US Oncology Research and the United Network of US Oncology participated in studies that will be presented in oral and poster presentations at this year’s ASCO. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 40 FDA approved cancer fighting therapies.

Presentations that US Oncology affiliated physicians are part of include:


    Oral Abstracts:
    Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center:
           Tuesday, June 08,  9:30AM - 12:30 PM (10:45 AM)  E Hall D1
        -- A meta-analysis of overall survival data from three randomized
           trials of bevacizumab (BV) and first-line chemotherapy as treatment
           for patients with metastatic breast cancer (MBC)

    Joanne Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center
           Tuesday, June 08,  9:30 AM - 12:30 PM (9:30 AM) E Hall D1
        -- A phase III study (EMBRACE) of eribulin mesylate versus treatment
           of physician's choice in patients with locally recurrent or
           metastatic breast cancer previously treated with an anthracycline
           and a taxane.

    Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center;
    Kathryn Kolibaba, MD, Northwest Cancer Specialists - Vancouver Cancer
    Center
    Thomas Boyd, MD, North Star Lodge Cancer Center, Yakima, Wash.
           Saturday, June 05,   1:00 - 4:00 PM (3:45 PM)    E354a
        -- Effect of BTK inhibitor PCI-32765 monotherapy on responses in
           patients with relapsed aggressive NHL: Evidence of antitumor
           activity from a phase I study

    William R. Berry, MD, Cancer Centers of North Carolina - Raleigh
           Sunday, June 06,     9:30 AM - 12:30 PM  (11:15 AM)   E Hall D2
        -- Docetaxel (D) plus high-dose calcitriol versus D plus prednisone
           (P) for patients (Pts) with progressive castration-resistant
           prostate cancer (CRPC):
           Results from the phase III ASCENT2 trial.

    Late Breaking Oral Presentation:
    Michael G. Teneriello, MD, Texas Oncology - Austin Central
           Sunday, June 06,   9:30 AM - 12:30 PM (11:45 AM)   E Arie Crown
           Theater
        -- Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus
           carboplatin (C) followed by elective T consolidation in advanced
           ovarian cancer (OC): Final safety and efficacy report.

    Clinical Science Symposium:
    Daniel D. Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)
           Sunday, June 06,   8:00 AM - 9:30 AM (8:45 AM)    E345a
        -- Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in
           advanced solid tumors.

    Donald A. Richards, MD, PhD, Texas Oncology - Tyler
           Monday, June 07,  9:45 AM - 11:15 AM (10:15 AM) E Arie Crown
           Theater
        -- Efficacy and safety of farletuzumab, a humanized monoclonal
           antibody to folate receptor alpha, in platinum-sensitive relapsed
           ovarian cancer subjects:
           Final data from a multicenter phase II study.       

    Poster Discussions:
    Michael G. Teneriello, MD, Texas Oncology - Austin Central
           Poster #5  Sunday , June 06,    2:00 PM - 6:00 PM  E450a
           Discussion  5:00 PM - 6:00 PM   E Arie Crown Theater
        -- PRECEDENT: a randomized phase II trial comparing EC145 and
           pegylated liposomal doxorubicin (PLD) in combination, versus PLD
           alone, in subjects with platinum-resistant ovarian cancer  Poster
           discussion

    Mark Fleming, MD, Virginia Oncology Associates - Hampton
    Michael Kolodziej, MD, New York Oncology Hematology - Albany Medical
    Center
    Sanjay Awasthi, MD, Texas Oncology - Arlington South
    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer
    Center
    Danko Martincic, MD, Cancer Care Northwest - Spokane Valley
    Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
    Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research
           Poster #12  Monday, June 07,    8:00 AM - 12:00 PM   450a
           Discussion 12 - 1 PM    E Hall D2
        -- Results of a randomized phase II study of mitoxantrone vs
           mitoxantrone with cetuximab in metastatic castrate resistant
           prostate cancer previously treated with docetaxel-based
           chemotherapy.  Poster discussion

    Donald A. Richards, MD, PhD, Texas Oncology - Tyler
    Joe Stephenson, MD, Cancer Centers of The Carolinas
    Lawrence E. Garbo, MD, New York Oncology Hematology - Albany Medical Center
           Poster #23  Friday, June 04,  2:00PM - 6:00PM E 450b
           Discussion   5:00 - 6:00 PM       E354a
        -- A placebo-controlled, randomized phase II study of conatumumab (C)
           or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients
           (pts) with metastatic pancreatic cancer (mPC).

    Donald A. Richards, MD, PhD, Texas Oncology - Tyler
           Poster #22  Tuesday, June 08, 8:00 AM - 12:00 PM    S403
           Discussion   11:00 AM - 12:00 PM     S406 (Vista room)
        -- Final results of a randomized phase II study of perifosine in
           combination with capecitabine (P-CAP) versus placebo plus
           capecitabine (CAP) in patients (pts) with second- or third-line
           metastatic colorectal cancer (mCRC).

    Donald A. Richards, MD, PhD, Texas Oncology - Tyler
    Lawrence E. Garbo, MD, New York Oncology Hematology
    Joe Stephenson, MD, Cancer Centers of The Carolinas
           Poster #23  Friday, June 04,    2:00 PM - 6:00 PM     E450b
           Discussion     5:00 PM - 6:00 PM    E354a
        -- A placebo-controlled, randomized phase II study of conatumumab (C)
           or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients
           (pts) with metastatic pancreatic cancer (mPC).

    Robert N. Raju, MD, Dayton Oncology & Hematology - Kettering
           Poster #15  Saturday, June 05,   8:00 AM - 12:00 PM E450a
           Discussion      12:00 PM - 1:00 PM     E354a
        -- A phase I dose-escalation study of the Hsp90 inhibitor STA-9090
           administered once weekly in patients with solid tumors.

    Michael G. Teneriello, MD, Texas Oncology - Austin Central
           Poster #5  Sunday, June 06,   2:00 PM - 6:00 PM E450a
           Discussion   5:00 PM - 6:00 PM    E Arie Crown Theater
        -- PRECEDENT: a randomized phase II trial comparing EC145 and
           pegylated liposomal doxorubicin (PLD) in combination, versus PLD
           alone, in subjects with platinum-resistant ovarian cancer

    Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis
           Poster #1  Tuesday, June 08,   8:00 AM - 12:00 PM E450a
           Discussion    11:00 AM - 12:00 PM   E353
        -- Evaluation of a urea/lactic acid-based topical keratolytic agent
           (ULABTKA) for prevention of capecitabine-induced hand and foot
           syndrome (HFS): NCCTG trial N05C5.

    Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis
           Poster #10  Saturday, June 05,    8:00 AM - 12:00 PM     S103
           Discussion   12:00 PM - 1:00 PM     S100b
        -- NCCTG phase II trial of bevacizumab in combination with sorafenib
           in recurrent GBM

    General Posters:
    Matthew Galsky, MD, Comprehensive Cancer Centers of Nevada - Twain
    Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
    Beth Hellerstedt, MD, Texas Oncology - Austin Central
    Scott McKenney, MD, Texas Oncology - Mamie McFadden Ward Cancer Center
    Beaumont
    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer
    Center
    Mary A. Rauch; Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology
    Research
           Poster #1H  Monday, June 07,  1:00 PM - 5:00 PM    S Hall A2
        -- Phase II study of gemcitabine, cisplatin, and sunitinib in patients
           with advanced urothelial carcinoma. 

    David McCollum, MD, Texas Oncology - Baylor Sammons Cancer Center
    Darren M. Kocs, MD, Texas Oncology - Round Rock
    Punit Chadha, MD, Texas Oncology - South Austin
    Donald A. Richards, MD, PhD, Texas Oncology - Tyler
    Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research
           Poster #14D  Sunday, June 06,  2:00 PM - 6:00 PM      S Hall A2
        -- A randomized Phase II trial of preoperative chemoradiotherapy with
           or without cetuximab in locally-advanced adenocarcinoma of the
           rectum.

    Thomas H. Cartwright, MD, Ocala Oncology Center
    Matthew Clayton; Jody Garey, PharmD; Kristi A. Boehm, US Oncology Research
    on behalf of US Oncology Pathways Task Force
           Poster #13C  Sunday, June 06,  2:00 PM - 6:00 PM  S Hall A2
        -- Use of an Electronic Health Record (iKnowMed), in conjunction with
           evidence-based pathways, permits more complete data capture for
           outcome measurement in colorectal cancer patients treated with 1st-
           line therapy in the US Oncology network.

    Marcus A. Neubauer, MD, Kansas City Cancer Center - Southwest
    Debra A. Patt, MD, Texas Oncology - Austin Central
    Janet L. Espirito, PharmD; Matthew Clayton; US Oncology Pathways Task
    Force
           Poster #27G  Monday, June 07,   1:00 PM - 5:00 PM    S Hall A2
        -- Combination vs. sequential chemotherapy for metastatic breast
           cancer: An evaluation of outcomes from a community oncology network.

    Susan N. Hoang, PharmD; Innovent Oncology
    J. Russell Hoverman, MD, Texas Oncology
    Brian Turnwald; US Oncology Pathways Task Force
           Poster #34A  Monday, June 07,      1:00 PM - 5:00 PM      S Hall A2
        -- 2nd line pancreatic cancer therapy: Patterns of care and survival.

    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer
    Center
           Poster #7A  Monday, June 07,   1:00 PM - 5:00 PM    S Hall A2
        -- Long-term sorafenib safety profile in > 700 patients with renal
           cell carcinoma treated for 12 to 42 months.

    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer
    Center
           Poster #5H  Monday, June 07,   1:00 PM - 5:00 PM    S Hall A2
        -- Sorafenib (SOR) safety profile in >4600 patients (pts) with renal
           cell carcinoma (RCC): assessment at 3-month (mo) intervals using an
           integrated database of 8 company-sponsored studies       

    Steve K. Gruschkus, PhD; Clara Chen; Michael T. Forsyth: US Oncology
           Poster #20C  Saturday,  June 05     2:00 PM - 6:00 PM     S Hall A2

        -- First line patterns of care and outcomes of HER2 (+) breast cancer
           patients who progressed after receiving adjuvant trastuzumab in the
           outpatient community setting.

    J. Russell Hoverman, MD, Texas Oncology
    Steve K. Gruschkus, PhD; Michael T. Forsyth; Clara Chen: US Oncology
           Poster #35D  Monday, June 07,     1:00 PM - 5:00 PM     S Hall A2
        -- Impact of comorbidities on clinical and economic outcomes among
           patients with advanced non-small cell lung cancer (NSCLC) receiving
           care in the community-based outpatient setting.

    Mary Ann K. Allison, MD, Comprehensive Cancer Centers of Nevada
           Poster #14D  Monday, June 07,   8:00 AM - 12:00 PM    S Hall A2
        -- Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in
           combination with letrozole for first-line treatment of patients
           with ER-positive, HER2-negative breast cancer.

    Allen L. Cohn, MD, Rocky Mountain Cancer Centers
           Poster #8F  Saturday,  June 05    2:00 PM - 6:00 PM    S Hall A2
        -- Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic
           colorectal cancer (mCRC): Initial results from ARIES, a second BV
           observational cohort study (OCS).

    Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
    Jessica D. Jensen; Lina Asmar, PhD: US Oncology Research
           Poster #24A  Saturday, June 05,   2:00 PM - 6:00 PM    S Hall A2
        -- Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer

    Allen L. Cohn, MD, Rocky Mountain Cancer Centers
           Poster #8G  Saturday, June 05    2:00 PM - 6:00 PM   S Hall A2
        -- Clinical outcomes in bevacizumab (BV)-treated patients (pts) with
           metastatic colorectal cancer (mCRC): Results from ARIES
           observational cohort study (OCS) and confirmation of BRiTE data on
           BV beyond progression (BBP).

    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center
           Poster #4E  Monday, June 07,    1:00 PM - 5:00 PM    S Hall A2
        -- TWiST analysis to estimate overall benefit for metastatic renal
           cell carcinoma (mRCC) patients (pts) treated in a phase 3 trial of
           sunitinib vs. interferon-alfa (IFN-a)

    Nicholas Robert, MD, Fairfax-Northern Virginia Hematology-Oncology
           Poster #17H  Saturday, June 05,     2:00 PM - 6:00 PM     S Hall A2
        -- Efficacy of capecitabine (C)-based therapy in patients with first-
           line metastatic breast cancer (MBC) previously treated with
           adjuvant anthracyclines and taxanes.

    Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics
    Research Institute (TGen)
           Poster #1C  Monday, June 07,    8:00 AM - 12:00 PM    S Hall A2
        -- A first-in-human phase I study to evaluate the pan-PI3K inhibitor
           GDC-0941 administered QD or BID in patients with advanced solid
           tumors.

    Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
           Poster #2C  Monday, June 07,   8:00 AM - 12:00 PM   S Hall A2
        -- Correlation of disease-free survival at 2 to 3 years and 5-year
           overall survival in patients with muscle-invasive bladder cancer
           undergoing radical cystectomy.

    Daniel Von Hoff, MD,  FACP, US Oncology Research and Translational
    Genomics Research Institute (TGen)
           Poster #5F  Monday, June 07,    8:00 AM - 12:00 PM   S Hall A2
        -- Final results from a phase I study of oral TRC102 (methoxyamine
           HCl), an inhibitor of base-excision repair, to potentiate the
           activity of pemetrexed in patients with refractory cancer.

    Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics
    Research Institute (TGen)
           Poster #16D  Monday, June 07,    8:00 AM - 12:00 PM    S Hall A2
        -- Results from a phase I, dose-escalation study of PX-478, an orally
           available inhibitor of HIF-1a.

    Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics
    Research Institute (TGen)
           Poster #25F  Monday, June 07,   1:00 PM - 5:00 PM   S Hall A2
        -- Concomitant medication (CM) use in phase I and II cancer clinical
           trials(CCT): Effects on trial eligibility and potential
           interactions with study medications.

    Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis
           Poster #21A  Saturday, June 05,   8:00 AM - 12:00 PM   S Hall A2
        -- Phase II study of the histone deacetylase (HDAC) inhibitor
           belinostat for the treatment of myelodysplastic syndrome (MDS).

    Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center
    William R. Berry, MD, Cancer Centers of North Carolina - Raleigh
           Poster #9H  Monday, June 07,   1:00 PM - 5:00 PM  S Hall A2
        -- Use of changes in serum alkaline phosphatase to predict survival
           independent of PSA changes in men with castration-resistant
           prostate cancer and bone metastasis receiving chemotherapy: A
           retrospective analysis of the TAX327 trial.

    Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
           Poster #21E  Saturday, June 05,   2:00 PM - 6:00 PM  S Hall A2
        -- Differential gene expression analysis and correlation with outcome
           in HER2-positive metastatic breast cancer treated with HER2-
           targeted therapy.

    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer
    Center
           Poster #6C  Monday, June 07,    1:00 PM - 5:00 PM    S Hall A2
        -- Efficacy and safety of everolimus in elderly patients (pts) with
           metastatic renal cell carcinoma (mRCC).

    Karen L. Tedesco, MD, New York Oncology Hematology - Amsterdam
    Joanne L. Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center
    Cynthia R. Osborne, MD, Texas Oncology - Baylor Sammons Cancer Center
    Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City
           Poster #21G  Saturday, June 05,   2:00 PM - 6:00 PM   S Hall A2
        -- A phase II trial of trabectedin (T) in patients (pts) with HER2-
           positive and BRCA1/2 germ-line-mutated metastatic breast cancer
            (MBC).

    Trials in Progress:
    Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City
    Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
           Poster #21F  Monday, June 07,   8:00 AM - 12:00 PM   S Hall A2
        -- Lapatinib and trastuzumab: Molecular effects and efficacy,
           separately and combined in breast cancer.

    Allen L. Cohn, MD, Rocky Mountain Cancer Centers
           Poster #36H  Monday, June 07,   8:00 AM - 12:00 PM    S Hall A2
        -- SPIRITT: a multi-center, open label, randomized, phase 2 clinical
           trial evaluating safety and efficacy of FOLFIRI with either
           panitumumab or bevacizumab as second-line treatment in patients
           with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors.

    Allen L. Cohn, MD, Rocky Mountain Cancer Centers
           Poster #41  Monday, June 07,   8:00 AM - 12:00 PM    S Hall A2
        -- A randomized, placebo-controlled, multicenter phase II adjuvant
           trial of the efficacy, immunogenicity, and safety of GI-4000 plus
           gemcitabine versus gemcitabine alone in patients with resected
           pancreatic cancer with activating ras mutations.

    Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center
    Gail Wright, MD, Florida Cancer Institute-New Hope - Hudson
           Poster #24F  Monday, June 07,    8:00 AM - 12:00 PM S Hall A2
       -- Three parallel randomized phase 2 trials of dasatinib plus hormonal
           therapy (HT) in advanced ER+ breast cancer (ER+ BC)

    Publish Only
    Sheetal Sheth, PharmD, Innovent Oncology
    J. Russell Hoverman, MD, Texas Oncology
    Brian Turnwald, US Oncology on behalf of US Oncology Pathways Task Force
        -- Cytotoxic therapy beyond 2nd-line in non-small cell lung cancer:
           patterns of care and survival.

    Clara Chen; Steve K. Gruschkus, PhD; US Oncology
    Nicholas J. Vogelzang, MD, Comprehensive Cancer Centers of Nevada
    Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer
    Center
    Michael T. Forsyth; William Lopez: US Oncology
        -- Observational study evaluating resource utilization among
           metastatic renal cell carcinoma patients treated with mTOR
           inhibitors in the outpatient community-based setting.

About US Oncology

US Oncology, Inc. is the nation’s leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with more than 1,300 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.

About US Oncology Research

US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary and the nation’s largest community-based cancer research network. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 80 sites in 200 locations managing more than 200 active trials at any given time. The research network has enrolled more than 42,900 patients in more than 700 trials since its inception and has contributed to the development of 40 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.

SOURCE US Oncology, Inc.


Source: newswire



comments powered by Disqus